Our hamster study also showed reduced accumulation of lung macrophages/monocytes and minimal bronchiolar changes in NACE2i-treated hamsters, indicating that targeting nuclear ACE2 is a promising therapeutic strategy to reduce chronic symptoms after acute COVID-19. Here, ACE2 is linked to COVID-19.